Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Osteosarcoma and related tumors

Cancer Genetics and Cytogenetics

Volumn 145, Issue 1, 2003, Pages 1-30

  Sandberg, Avery A ^a   Bridge, Julia A ^b  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; METHOTREXATE; PROTEIN MDM2; PROTEIN P14; PROTEIN P16; SCATTER FACTOR; TELOMERASE;

AUTOCRINE EFFECT; BONE TUMOR; CANCER GENETICS; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CHONDROSARCOMA; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA DETERMINATION; DNA MICROARRAY; DRUG MEGADOSE; DRUG UPTAKE; ENZYME ACTIVITY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE INACTIVATION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPE; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; MUTATION; NONHUMAN; ONCOGENE C FOS; ONCOGENE C MYC; ONCOGENE NEU; OSTEOSARCOMA; PAGET BONE DISEASE; PARACRINE SIGNALING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; REVIEW; SOFT TISSUE TUMOR; TELOMERE; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

EID: 0042745572     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(03)00105-5     Document Type: Article

References (404)

1. Sandberg A.A., Bridge J.A. The cytogenetics of bone and soft tissue tumors. 1994;RG Landes Co. Austin.
2. Bell W., Siegal G.P. Osteosarcoma. Cullinane C., Burchill S., Squire J., Lewis I., O'Leary J. Molecular biology and pathology of paediatric cancer. 2002;Oxford University Press, London.
3. Dorfman H.D., Czerniak B. Bone tumors. 1998;Mosby, St. Louis.
4. Campanacci M. Bone and soft tissue tumors. 2nd edition:1999;Springer-Verlag, New York.
5. Dahlin D.C. Pathology of osteosarcoma. Clin Orthop. 111:1975;23-32.
6. Meyers P.A., Heller G., Healey J., Huvos A., Lane J., Marcove R., Applewhite A., Vlamis V., Rosen G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 10:1992;5-15.
7. Meyers P.A., Heller G., Healey J.H., Huvos A., Applewhite A., Sun M., LaQuaglia M. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 11:1993;449-453.
8. Meyers P.A., Gorlick R. Osteosarcoma. Pediatr Clin North Am. 44:1997;973-989.
9. Weiss S.W., Goldblum J.R. Enzinger and Weiss' soft tissue tumors. 4th edition:2001;Mosby, St. Louis.
10. Mark R.J., Poen J., Tran L.M., Fu Y.S., Selch M.T., Parker R.G. Postirradiation sarcomas: a single-institution study and review of the literature. Cancer. 73:1994;2653-2662.
11. Keel S.B., Jaffe K.A., Nielsen G.P., Rosenberg A.E. Orthopaedic implant-related sarcoma: a study of twelve cases. Mod Pathol. 14:2001;969-977.
12. Draper G.J., Sanders B.M., Kingston J.E. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 53:1986;661-671.
13. Arndt C.A.S., Crist W.M. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 341:1999;342-352.
14. Dahlin D.C., Unni K.K. Osteosarcomas of bone and its important recognizable varieties. Am J Surg Pathol. 1:1977;61-72.
15. Bieling P., Rehan N., Winkler P., Helmke K., Maas R., Fuchs N., Bielack S., Heise U., Jürgens H., Treuner J., Romanowski R., Exner U., Kotz R., Winkler K. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 14:1996;848-858.
16. Ferguson W.S., Goorin A.M. Current treatment of osteosarcoma. Cancer Invest. 19:2001;292-315.
17. Jaffe N., Carrasco H., Raymond K., Ayala A., Eftekhari F. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer. 95:2002;2202-2210.
18. Klein M.L., Kenan S., Lewis M.M. Osteosarcoma: clinical and pathological considerations. Orthop Clin North Am. 20:1989;327-345.
19. Grundmann E., Roessner A., Ueda Y., Schneider-Stock R., Radig K. Current aspects of the pathology of osteosarcoma. Anticancer Res. 15:1995;1023-1033.
20. Grundmann E., Ueda Y., Schneider-Stock R., Roessner A. New aspects of cell biology in osteosarcoma. Pathol Res Pract. 191:1995;563-570.
21. Dahlin D.C., Unni K.K. Bone tumors: general aspects and data on 8,542 cases. 4th edition:1986;Thomas, Springfield, IL. pp. 227-307.
22. Link M.P., Eilber F. Osteosarcoma. Pizzo P.A., Poplack D.G. Principles and practice of pediatric oncology. 3rd edition:1997;889-920 Lippincott-Raven, Philadelphia.
23. Hopper K.D., Eggli K.D., Haseman D.B. Osteosarcomatosis and metastatic osteosarcoma. Humphrey G.B. Osteosarcoma in adolescents and young adults. 1993;163-171 Kluwer Academic Publishers, Boston.
24. Chung E.B., Enzinger F.M. Extraskeletal osteosarcoma. Cancer. 60:1987;1132-1142.
25. Fletcher C.D.M., Unni K.K. Pathology and genetics of tumours of soft tissue and bone. World Health Organization Classification of Tumours. 2002;IARC Press, Lyon.
26. Hansen M.F. Molecular genetic considerations in osteosarcoma. Clin Orthop. 270:1991;237-246.
27. Ladanyi M., Gorlick R. Molecular pathology and molecular pharmacology of osteosarcoma. Pediatr Pathol Mol Med. 19:2000;391-413.
28. Ladanyi M., Bridge J.A. Contribution of molecular genetic data to the classification of sarcomas. Hum Pathol. 31:2000;532-538.
29. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 33:1997;787-791.
30. Bryan T.M., Englezou A., Dalla-Pozza L., Dunham M.A., Reddel R.R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. 3:1997;1271-1274.
31. Meyerson M. Role of telomerase in normal and cancer cells. J Clin Oncol. 18:2000;2626-2634.
32. Hahn W.C. Telomerase and cancer: where and when? Clin Cancer Res. 7:2001;2953-2954.
33. Buys C.H.C.M. Telomeres, telomerase, and cancer. N Engl J Med. 342:2000;1282-1283.
34. Scheel C., Schaefer K.-L., Jauch A., Keller M., Wai D., Brinkschmidt C., van Valen F., Boecker W., Dockhorn-Dworniczak B., Poremba C. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene. 20:2001;3835-3844.
35. Henson J.D., Neumann A.A., Yeager T.R., Reddel R.R. Alternative lengthening of telomeres in mammalian cells. Oncogene. 21:2002;598-610.
36. Grobelny J.V., Kulp-McEliece M., Broccoli D. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway. Hum Mol Genet. 10:2001;1953-1961.
37. Vasef M.A., Ross J.S., Cohen M.B. Telomerase activity in human solid tumors: diagnostic utility and clinical applications. Am J Clin Pathol. 112:(suppl 1):1999;S68-S75.
38. Friend S.H., Bernards R., Rogelj S., Weinberg R.A., Rapaport J.M., Albert D.M., Dryja T.P. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 323:1986;643-646.
39. Hansen M.F., Koufos A., Gallie B.L., Phillips R.A., Fodstad Ø, Brøgger A., Gedde-Dahl T., Cavenee W.K. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA. 82:1985;6216-6220.
40. Dryja T.P., Rapaport J.M., Epstein J., Goorin A.M., Weichelbaum R., Koufos A., Cavenee W.K. Chromosome 13 homozygosity in osteosarcoma without retinoblastoma. Am J Hum Genet. 38:1986;59-66.
41. Ozaki T., Ikeda S., Kawai A., Inoue H., Oda T. Alterations of retinoblastoma susceptibility gene accompanied by c-MYC amplification in human bone and soft tissue tumors. Cell Mol Biol (Noisy-le-grand). 39:1993;235-242.
42. Dickman P.S., Barmada M., Gollin S.M., Blatt J. Malignancy after retinoblastoma: secondary cancer or recurrence? Hum Pathol. 28:1997;200-205.
43. Wong F.L., Boice J.D. Jr., Abramson D.H., Tarone R.E., Kleinerman R.A., Stovall M., Goldman M.B., Seddon J.M., Tarbell N., Fraumeni J.F. Jr., Li F.P. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA. 278:1997;1262-1267.
44. Chauveinc L., Mosseri V., Quintana E., Desjardins L., Schlienger P., Doz F., Dutrillaux B. Osteosarcoma following retinoblastoma: age at onset and latency period. Ophthalmic Genet. 22:2001;77-88.
45. Kitchin F.D., Ellsworth R.M. Pleiotropic effects of the gene for retinoblastoma. J Med Genet. 11:1974;244-246.
46. Abramson D.H., Ellsworth R.M., Kitchin F.D., Tung G. Second nonocular tumors in retinoblastoma survivors: are they radiation-induced? Ophthalmology. 91:1984;1351-1355.
47. Araki N., Uchida A., Kimura T., Yoshikawa H., Aoki Y., Ueda T., Takai S.-I., Miki T., Ono K. Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop. 270:1991;271-277.
48. Wunder J.S., Czitrom A.A., Kandel R., Andrulis I.L. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl Cancer Inst. 83:1991;194-200.
49. Scholz B., Kabisch H., Weber B., Röser K., Delling G., Winkler K. Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol. 9:1992;125-137.
50. Wadayama B., Toguchida J., Shimizu T., Ishizaki K., Sasaki M.S., Kotoura Y., Yamamuro T. Mutation spectrum of the retinoblastoma gene in osteosarcoma. Cancer Res. 54:1994;3042-3048.
51. Belchis D.A., Meece C.A., Benko F.A., Rogan P.K., Williams R.A., Gocke C.D. Loss of heterozygosity and microsatellite instability at the retinoblastoma locus in osteosarcomas. Diagn Mol Pathol. 5:1996;214-219.
52. Belchis D.A., Gocke C.D. Alterations in the RB, p16, and cyclin D1 cell cycle control pathway in osteosarcomas. Pediatr Pathol Mol Med. 19:2000;377-389.
53. Miller C.W., Aslo A., Won A., Tan M., Lampkin B., Koeffler H.P. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol. 122:1996;559-565.
54. Toguchida J., Ishizaki K., Sasaki M.S., Ikenaga M., Sugimoto M., Kotoura Y., Yamamuro T. Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcomas. Cancer Res. 48:1988;3939-3943.
55. Benassi M.S., Molendini L., Gamberi G., Ragazzini P., Sollazzo M.R., Merli M., Asp J., Magagnoli G., Balladelli A., Bertoni F., Picci P. Alteration of pRB/p16/cdk4 regulation in human osteosarcoma. Int J Cancer. 84:1999;489-493.
56. Alonso J., García-Miguel P., Abelairas J., Mendiola M., Pestaña Á. A microsatellite fluorescent method for linkage analysis in familial retinoblastoma and deletion detection at the RB1 locus in retinoblastoma and osteosarcoma. Diagn Mol Pathol. 10:2001;9-14.
57. Yamaguchi T., Toguchida J., Yamamuro T., Kotoura Y., Takada N., Kawaguchi N., Kaneko Y., Nakamura Y., Sasaki M.S., Ishizaki K. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res. 52:1992;2419-2423.
58. Feugeas O., Guriec N., Babin-Boilletot A., Marcellin L., Simon P., Babin S., Thyss A., Hofman P., Terrier P., Kalifa C., Brunat-Mentigny M., Patricot L.-M., Oberling F. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol. 14:1996;467-472.
59. Brachman D.G., Hallahan D.E., Beckett M.A., Yandell D.W. Weichselbaum RR. p53 mutations and abnormal retinoblastoma protein in radiation-induced human sarcomas. Cancer Res. 51:1991;6393-6396.
60. Nevins J.R., Leone G., De Gregori J., Jakoi L. Role of the RB/E2F pathway in cell growth control. J Cell Physiol. 173:1997;233-236.
61. 1 phase regulation in osteosarcoma. Int J Cancer. 74:1997;518-522.
62. Boehm A.K., Neff J.R., Squire J.A., Bayani J., Nelson M., Bridge J.A. Cytogenetic findings in 36 osteosarcoma specimens and a review of the literature. Pediatr Pathol Mol Med. 19:2000;359-376.
63. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 68:1996;67-108.
64. Nielsen G.P., Burns K.L., Rosenberg A.E., Louis D.N. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol. 153:1998;159-163.
65. Pellín A., Boix-Ferrero J., Carpio D., López-Terrada D., Carda C., Navarro S., Peydró-Olaya A., Triche T.J., Llombart-Bosch A. Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas. Diagn Mol Pathol. 6:1997;333-341.
66. INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis. Oncogene. 18:1999;3930-3935.
67. Wei G., Lonardo F., Ueda T., Kim T., Huvos A.G., Healey J.H., Ladanyi M. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer. 80:1998;199-204.
68. INK4A expression correlates with decreased survival in pediatric osteosarcomas. Int J Cancer. 95:2001;34-38.
69. Patiño-García A., Sierrasesúmaga L. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet Cytogenet. 98:1997;50-55.
70. Ruas M., Peters G. The p16 INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1378:1998;115-177.
71. Benassi M.S., Molendini L., Gamberi G., Magagnoli G., Ragazzini P., Gobbi G.A., Sangiorgi L., Pazzaglia L., Asp J., Brantsing C., Picci P. Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma. Cancer. 92:2001;3062-3067.
72. Park Y.-B., Park M.J., Kimura K., Shimizu K., Lee S.H., Yokota J. Alterations of the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet. 133:2002;105-111.
73. Kanoe H., Nakayama T., Murakami H., Hosaka T., Yamamoto H., Nakashima Y., Tsuboyama T., Nakamura T., Sasaki M.S., Toguchida J. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutations. Anticancer Res. 18:1998;2317-2322.
74. Ragazzini P., Gamberi G., Benassi M.S., Orlando C., Sestini R., Ferrari C., Molendini L., Sollazzo M.R., Merli M., Magagnoli G., Bertoni F., Bohling T., Pazzagli M., Picci P. Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma. Cancer Detect Prev. 23:1999;129-136.
75. Su Y.A., Lee M.M., Hutter C.M., Meltzer P.S. Characterization of a highly conserved gene (OS4) amplified with CDK4 in human sarcomas. Oncogene. 15:1997;1289-1294.
76. Cordon-Cardo C. Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol. 147:1995;545-560.
77. Khatib Z.A., Matsushime H., Valentine M., Shapiro D.N., Sherr C.J., Look A.T. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 53:1993;5535-5541.
78. Schmidt E.E., Ichimura K., Reifenberger G., Collins V.P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54:1994;6321-6324.
79. Maelandsmo G.M., Berner J.-M., Flørenes V.A., Forus A., Hovig E., Fodstad Ø., Myklebost O. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas-relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer. 72:1995;393-398.
80. Elkahloun A.G., Bittner M., Hoskins K., Gemmill R., Meltzer P.S. Molecular cytogenetic characterization and physical mapping of 12q13-15 amplification in human cancers. Genes Chromosomes Cancer. 17:1996;205-214.
81. Ladanyi M., Lewis R., Jhanwar S.C., Gerald W., Huvos A.G., Healey J.H. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol. 175:1995;211-217.
82. Berner J.-M., Forus A., Elkahloun A., Meltzer P.S., Fodstaf Ø., Myklebost O. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer. 17:1996;254-259.
83. Reifenberger G., Ichimura K., Reifenberger J., Elkahloun A.G., Meltzer P.S., Collins V.P. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res. 56:1996;5141-5145.
84. Wolf M., Aaltonen L.A., Szymanska J., Tarkkanen M., Blomqvist C., Berner J.-M., Myklebost O., Knuutila S. Complexity of 12q13-22 amplicon in liposarcoma: microsatellite repeat analysis. Genes Chromosomes Cancer. 18:1997;66-70.
85. Molendini L., Benassi M.S., Magagnoli G., Merli M., Sollazzo M.R., Ragazzini P., Gamberi G., Ferrari C., Balladelli A., Bacchini P., Picci P. Prognostic significance of cyclin expression in human osteosarcoma. Int J Oncol. 12:1998;1007-1011.
86. Ueki K., Ono Y., Henson J.W., Efird J.T., von Deimling A., Louis D.N. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56:1996;150-153.
87. INK4A/CDKN2/MTS1 mutations independent of P53 status in soft tissue sarcomas. J Pathol. 184:1998;14-17.
88. Hollstein M., Shomer B., Greenblatt M., Soussi T., Hovig E., Montesano R., Harris C.C. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res. 24:1996;141-146.
89. El-Deiry W.S. Regulation of P53 downstream genes. Semin Cancer Biol. 8:1998;345-357.
90. Fletcher J.A., Gebhardt M.C., Kozakewich H.P. Cytogenetic aberrations in osteosarcomas: nonrandom deletions, rings, and double-minute chromosomes. Cancer Genet Cytogenet. 77:1994;81-88.
91. Hoogerwerf W.A., Hawkins A.L., Perlman E.J., Griffin C.A. Chromosome analysis of nine osteosarcomas. Genes Chromosomes Cancer. 9:1994;88-92.
92. Hung J., Anderson R. p53: functions, mutations and sarcomas. Acta Orthop Scand Suppl. 273:1997;68-73.
93. Hansen R., Oren M. P53: from inductive signal to cellular effect. Curr Opin Genet Dev. 7:1997;46-51.
94. Levine A.J. P53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
95. Chandar N., Billig B., McMaster J., Novak J. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer. 65:1992;208-214.
96. Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol. 10:1990;5772-5781.
97. Masuda H., Miller C., Koeffler H.P., Battifora H., Cline M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA. 84:1987;7716-7719.
98. Romano J.W., Ehrhart J.C., Duthu A., Kim C.M., Appella E., May P. Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line. Oncogene. 4:1989;1483-1488.
99. Miller C.W., Aslo A., Tsay C., Slamon D., Ishizaki K., Toguchida J., Yamamuro T., Lampkin B., Koeffler H.P. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res. 50:1990;7950-7954.
100. Miller C.W., Aslo A., Campbell M.J., Kawamata N., Lampkin B.C., Koeffler H.P. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet. 86:1996;136-142.
101. Mulligan L.M., Matlashewski G.J., Scrable H.J., Cavenee W.K. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA. 87:1990;5863-5867.
102. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83.
103. Toguchida J., Yamaguchi T., Ritchie B., Beauchamp R.L., Dayton S.H., Herrera G.E., Yamamuro T., Kotoura Y., Sasaki M.S., Little J.B., Weichselbaum R.R., Ishizaki K., Yandell D.W. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 52:1992;6194-6199.
104. Toguchida J., Yamaguchi T., Dayton S.H., Beauchamp R.L., Herrera G.E., Ishizaki K., Yamamuro T., Meyers P.A., Little J.B., Sasaki M.S., Weichselbaum R.R., Yandell D.W. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med. 326:1992;1301-1308.
105. Andreassen Å., Øyjord T., Hovig E., Holm R., Flørenes V.A., Nesland J.M., Myklebost O., Høie J., Bruland Ø.S., Børresen A.-L., Fodstad Ø. p53 abnormalities in different subtypes of human sarcomas. Cancer Res. 53:1993;468-471.
106. Smith-Sørensen B., Gebhardt M.C., Kloen P., McIntyre J., Aguilar F., Cerutti P., Børresen A.-L. Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum Mutat. 2:1993;274-285.
107. Ueda Y., Dockhorn-Dworniczak B., Blasius S., Mellin W., Wuisman P., Böcker W., Roessner A. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol. 119:1993;172-178.
108. Wadayama B., Toguchida J., Yamaguchi T., Sasaki M.S., Kotoura Y. Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer. 68:1993;1134-1139.
109. Guo W., Wang X., Feng C. P53 gene abnormalities in osteosarcoma. Chin Med J (Engl). 109:1996;752-755.
110. Bodey B., Gröger A.M., Bodey B. Jr., Siegel S.E., Kaiser H.E. Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res. 17:1997;493-498.
111. Lonardo F., Ueda T., Huvos A.G., Healey J., Ladanyi M. p53 and MDM2 alterations in osteosarcomas: correlations with clinicopathologic features and proliferative rate. Cancer. 79:1997;1541-1547.
112. Sztán M., Pápai Z., Szendrõi M., van der Looij M., Oláh E. Allelic losses from chromosome 17 in human osteosarcomas. Pathol Oncol Res. 3:1997;115-120.
113. Oliveira P., Nogueira M., Pinto A., Almeida O. Analysis of p53 expression in osteosarcoma of the jaw: correlation with clinicopathologic and DNA ploidy findings. Hum Pathol. 28:1997;1361-1365.
114. Radig K., Schneider-Stock R., Haeckel C., Neumann W., Roessner A. p53 gene mutations in osteosarcomas of low-grade malignancy. Hum Pathol. 29:1998;1310-1316.
115. Schneider-Stock R., Radig K., Oda Y., Mellin W., Rys J., Niezabitowski A., Roessner A. p53 gene mutations in soft-tissue sarcomas - correlations with p53 immunohistochemistry and DNA ploidy. J Cancer Res Clin Oncol. 123:1997;211-218.
116. Castresana J.S., Rubio M.-P., Gómez L., Kreicbergs A., Zetterberg A., Barrios C. Detection of TP53 gene mutations in human sarcomas. Eur J Cancer. 31A:1995;735-738.
117. Ladanyi M., Cha C., Lewis R., Jhanwar S.C., Huvos A.G., Healey J.H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 53:1993;16-18.
118. Mousses S., McAuley L., Bell R.S., Kandel R., Andrulia I.L. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol. 9:1996;1-6.
119. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in P53-mutant mice. Curr Biol. 4:1994;1-7.
120. Li F.P., Fraumeni J.F. Jr., Mulvihill J.J., Blattner W.A., Dreyfus M.G., Tucker M.A., Miller R.W. A cancer family syndrome in twenty-four kindreds. Cancer Res. 48:1988;5358-5362.
121. Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1990;1233-1238.
122. Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., Andersen T.I., Børresen A.-L., Li F.P., Garber J., Strong L.C. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med. 326:1992;1309-1315.
123. Porter D.E., Holden S.T., Steel C.M., Cohen B.B., Wallace M.R., Reid R. A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families. J Bone Joint Surg Br. 74:1992;883-886.
124. Srivastava S., Zou Z.Q., Pirollo K., Blattner W., Chang E.H. Germ-line transmission of a mutated P53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 348:1990;747-749.
125. McIntyre J.F., Smith-Sørensen B., Friend S.H., Kassell J., Børresen A.-L., Yan Y.X., Russo C., Sato J., Barbier N., Miser J., Malkin D., Gebhardt M.C. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 12:1994;925-930.
126. Kleihues P., Schäuble B., zur Hausen A., Estève J., Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 150:1997;1-13.
127. Miller C.W., Ikezoe T., Krug U., Hofmann W.-K., Tavor S., Vegesna V., Tsukasaki K., Takeuchi S., Koeffler H.P. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer. 33:2002;17-21.
128. Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C.R., Shannon K.E., Lubratovich M., Verselis S.J., Isselbacher K.J., Fraumeni J.F., Birch J.M., Li F.P., Garber J.E., Haber D.A. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 286:1999;2528-2531.
129. Gokgoz N., Wunder J.S., Mousses S., Eskandarian S., Bell R.S., Andrulis I.L. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer. 92:2001;2181-2189.
130. Goto A., Kanda H., Ishikawa Y., Matsumoto S., Kawaguchi N., Machinami R., Kato Y., Kitagawa T. Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Jpn J Cancer Res. 89:1998;539-547.
131. Shew J.-Y., Ling N., Mendoza A.E., Fodstad Ø., Lee W.-H. Antibodies to the retinoblastoma gene product detect specific loss of pp110RB in osteosarcomas and synovial sarcomas. Oncogene Res. 1:1989;205-214.
132. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Clearly K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in p53 gene occur in diverse human tumour types. Nature (Lond). 342:1989;705-708.
133. Pompetti F., Stuppia L., Gatta V., Calabrese G., Gamberi G., Benassi M.S., Picci P., Palka G. Correlation between apoptosis and TP53 status in osteosarcoma. Cancer Genet Cytogenet. 105:1998;177-181.
134. Flørenes V.A., Maelandsmo G.M., Forus A., Andreassen Å., Myklebost O., Fodstad Ø. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst. 86:1994;1297-1302.
135. Freedman D.A., Levine A.J. Regulation of the p53 protein by the MDM2 oncoprotein: thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 59:1999;1-7.
136. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 26:1998;3453-3459.
137. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
138. Forus A., Flørenes V.A., Maelandsmo G.M., Meltzer P.S., Fodstad Ø., Myklebost O. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ. 4:1993;1065-1070.
139. Schlott T., Reimer S., Jahns A., Ohlenbusch A., Ruschenburg I., Nagel H., Droese M. Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumours. J Pathol. 182:1997;54-61.
140. Nakayama T., Toguchida J., Wadayama B., Kanoe H., Kotoura Y., Sasaki M.S. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer. 64:1995;342-346.
141. Yokoyama R., Schneider-Stock R., Radig K., Wex T., Roessner A. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathol Res Pract. 194:1998;615-621.
142. Kim H.-S., Jung H.-G., Oh J.H., Lee S.H. Multidrug resistance-associated protein (MRP) is expressed in osteosarcoma but is not a significant mechanism of drug resistance. Trans Orthop Res Soc, Poster 0855. 2001.
143. Kawaguchi K., Oda Y., Sakamoto A., Saito T., Tamiya S., Iwamoto Y., Tsuneyoshi M. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Mod Pathol. 15:2002;878-888.
144. Naka T., Fukuda T., Shinohara N., Iwamoto Y., Sugioka Y., Tsuneyoshi M. Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years: a clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma. Cancer. 76:1995;972-984.
145. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000.
146. Larsen C.J. p16INK4A: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. Oncogene. 12:1996;2041-2044.
147. ARF. Cell. 91:1997;555-557.
148. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723.
149. Zhang Y., Xiong Y., Yarden Y. ARF promotes MDM2 degradation and stabilizes P53: ARF-INK4A locus deletion impairs both the RB and P53 tumor suppression pathways. Cell. 92:1998;725-734.
150. Tao W., Levine A.J. P19(ARF) stabilizes P53 by blocking nucleo-cytoplasmic shuttling of MDM2. Proc Natl Acad Sci USA. 96:1999;6937-6941.
151. Ookawa K., Tsuchida S., Adachi J., Yokota J. Differentiation induced by RB expression and apoptosis induced by p53 expression in an osteosarcoma cell line. Oncogene. 14:1997;1389-1396.
152. Simons A., Schepens M., Forus A., Godager L., van Asseldonk M., Myklebost O., van Kessel A.G. A novel chromosomal region of allelic loss, 4q32-q34, in human osteosarcomas revealed by representational difference analysis. Genes Chromosomes Cancer. 26:1999;115-124.
153. Kruzelock R.P., Murphy E.C., Strong L.C., Naylor S.L., Hansen M.F. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. Cancer Res. 57:1997;106-109.
154. Himelstein B.P. Osteosarcoma and other bone cancers. Curr Opin Oncol. 10:1998;326-333.
155. Horstmann M.A., Pösl M., Scholz R.B., Anderegg B., Simon P., Baumgaertl K., Delling G., Kabisch H. Frequent reduction or loss of DCC gene expression in human osteosarcoma. Br J Cancer. 75:1997;1309-1317.
156. Nellissery M.J., Padalecki S.S., Brkanac Z., Singer F.R., Roodman G.D., Unni K.K., Leach R.J., Hansen M.F. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet. 63:1998;817-824.
157. Hansen M.F., Nellissery M.J., Bhatia P. Common mechanisms of osteosarcoma and Paget's disease. J Bone Miner Res. 14:(suppl 2):1999;39-44.
158. Nathrath M.H., Kuosaite V., Rosemann M., Kremer M., Poremba C., Wakana S., Yanagi M., Nathrath W.B.J., Höfler H., Imai K., Atkinson M.J. Two novel tumor suppressor gene loci on chromosome 6q and 15q in human osteosarcoma identified through comparative study of allelic imbalances in mouse and man. Oncogene. 21:2002;5975-5980.
159. Chen J.-R., Zhong Q., Wang J., Cameron R.S., Borke J.L., Isales C.M., Bolag R.J. Microarray analysis of Tbx2-directed gene expression: a possible role in osteogenesis. Mol Cell Endocrinol. 177:2001;43-54.
160. Kraus F., Haenig B., Kispert A. Cloning and expression analysis of the mouse T-box gene Tbx18. Mech Dev. 100:2001;83-86.
161. Kools P.F.J., Van de Ven W.J.M. Amplification of a rearranged form of the high-mobility group protein gene HMGIC in OsA-CI osteosarcoma cells. Cancer Genet Cytogenet. 91:1996;1-7.
162. Berner J.-M., Meza-Zepeda L.A., Kools P.F.J., Forus A., Schoenmakers E.F.P.M., Van de Ven W.J.M., Fodstad Ø., Myklebost O. HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene. 14:1997;2935-2941.
163. Broberg K., Tallini G., Höglund M., Lindstrand A., Toksvig-Larsen S., Mertens F. The tumor-associated gene HMGIC is expressed in normal and osteoarthritis-affected synovia. Mod Pathol. 14:2001;311-317.
164. Schoenmakers E.F.P.M., Wanschura S., Mols R., Bullerdiek J., Van den Berghe H., Van de Ven W.J.M. Recurrent rearrangements of the high mobility protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet. 10:1995;436-444.
165. Carbone M., Rizzo P., Procopio A., Giuliano M., Pass H.I., Gebhardt M.C., Mangham C., Hansen M., Malkin D.F., Bushart G., Pompetti F., Picci P., Levine A.S., Bergsagel J.D., Garcea R.L. SV40-like sequences in human bone tumors. Oncogene. 13:1996;527-535.
166. Butel J.S., Lednicky J.A. Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst. 91:1999;119-134.
167. Mendoza S.M., Konishi T., Miller C.W., Integration of SV40 in human osteosarcoma D.N.A. Oncogene. 17:1998;2457-2462.
168. Reifenberger G., Reifenberger J., Ichimura K., Meltzer P.S., Collins V.P. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, MDM2. Cancer Res. 54:1994;4299-4303.
169. Roberts W.M., Douglass E.C., Peiper S.C., Houghton P.J., Look A.T. Amplification of the GLI gene in childhood sarcomas. Cancer Res. 49:1989;5407-5413.
170. Meltzer P.S., Jankowski S.A., Dal Cin P., Sandberg A.A., Paz I.B., Coccia M.A. Identification and cloning of a novel amplified DNA sequence in human malignant fibrous histiocytoma derived from a region of chromosome 12 frequently rearranged in soft tissue tumors. Cell Growth Differ. 2:1991;495-501.
171. Su Y.A., Hutter C.M., Trent J.M., Meltzer P.S. Complete sequence analysis of a gene (OS-9) ubiquitously expressed in human tissues and amplified in sarcomas. Mol Carcinog. 15:1996;270-275.
172. Yotov W.V., Hamel H., Rivard G.-E., Champagne M.A., Russo P.A., Leclerc J.-M., Bernstein M.L., Levy E. Amplifications of DNA primase I (PRIM1) in human osteosarcoma. Genes Chromosomes Cancer. 26:1999;62-69.
173. Elkahloun A.G., Krizman D.B., Wang Z., Hofmann T.A., Roe B., Meltzer P.S. Transcript mapping in a 46-kb sequenced region at the core of 12q13.3
174. Forus A., Berner J.-M., Meza-Zepeda L.A., Saeter G., Mischke D., Fodstad Ø., Myklebost O. Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas. Br J Cancer. 78:1998;495-503.
175. Forus A., Weghuis D.O., Smeets D., Fodstad Ø., Myklebost O., van Kessel A.G. Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes Chromosomes Cancer. 14:1995;15-21.
176. Tarkkanen M., Elomaa I., Blomqvist C., Kivioja A.H., Kellokumpu-Lehtinen P., Böhling T., Valle J., Knuutila S. DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer. 84:1999;114-121.
177. Toguchida J., Ishizaki K., Nakamura Y., Sasaki M.S., Ikenaga M., Kato M., Sugimoto M., Kotoura Y., Yamamuro T. Assignment of common allele loss in osteosarcoma to the subregion 17p13. Cancer Res. 49:1989;6247-6251.
178. Hulsebos T.J.M., Bijleveld E.H., Oskam N.T., Westerveld A., Leenstra S., Hogendoorn P.C.W., Bras J. Malignant astrocytoma-derived region of common amplification in chromosomal band 17p12 is frequently amplified in high-grade osteosarcomas. Genes Chromosomes Cancer. 18:1997;279-285.
179. Simons A., Janssen I.M., Suijkerbuijk R.F., Veth R.P.H., Pruszczynski M., Hulsbergen-van de Kaa C.A., du Manoir S., van Kessel A.G. Isolation of osteosarcoma-associated amplified DNA sequences using representational difference analysis. Genes Chromosomes Cancer. 20:1997;196-200.
180. Cole M.D., McMahon S.B. The MYC oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene. 18:1999;2916-2924.
181. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene. 18:1999;3004-3016.
182. Pompetti F., Rizzo P., Simon R.M., Freidlin B., Mew D.J., Pass H.I., Picci P., Levine A.S., Carbone M. Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem. 63:1996;37-50.
183. Barrios C., Castresana J.S., Ruiz J., Kreicbergs A. Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma. J Orthop Res. 11:1993;556-563.
184. Barrios C., Castresana J.S., Kreicbergs A. Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification. Am J Clin Oncol. 17:1994;273-276.
185. Ladanyi M., Park C.K., Lewis R., Jhanwar S.C., Healey J.H., Huvos A.G. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol. 2:1993;163-167.
186. Ueda T., Healey J.H., Huvos A.G., Ladanyi M. Amplification of the MYC gene in osteosarcoma arising in Paget's disease. Sarcoma. 1:1998;131-134.
187. Gamberi G., Benassi M.S., Bohling T., Ragazzini P., Molendini L., Sollazzo M.R., Pompetti F., Merli M., Magagnoli G., Balladelli A., Picci P. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology. 55:1998;556-563.
188. Ruther U., Komitowski D., Schubert F.R., Wagner E.F. FOS expression induces bone tumors in transgenic mice. Oncogene. 4:1989;861-865.
189. Wang Z.-Q., Liang J., Schellander K., Wagner E.F., Grigoriadis A.E. C-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res. 55:1995;6244-6251.
190. Wu J.-X., Carpenter P.M., Gresens C., Keh R., Niman H., Morris J.W.S., Mercola D. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene. 5:1990;989-1000.
191. Franchi A., Calzolari A., Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch. 432:1998;515-519.
192. Kakar S., Mihalov M., Chachlani N.A., Ghosh L., Johnstone H. Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma. J Surg Oncol. 73:2000;125-126.
193. Onda M., Matsuda S., Higaki S., Iijima T., Fukushima J., Yokokura A., Kojima T., Horiuchi H., Kurokawa T., Yamamoto T. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 77:1996;71-78.
194. Maitra A., Wanzer D., Weinberg A.G., Ashfaq R. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer. 92:2001;677-683.
195. Gorlick R., Huvos A.G., Heller G., Aledo A., Beardsley G.P., Healey J.H., Meyers P.A. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 17:1999;2781-2788.
196. Akatsuka T., Wada T., Kokai Y., Kawaguchi S., Isu K., Yamashiro K., Yamashita T., Sawada N., Yamawaki S., Ishii S. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer. 94:2002;1397-1404.
197. Kilpatrick S.E., Geisinger K.R., King T.S., Sciarrotta J., Ward W.G., Gold S.H., Bos G.D. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol. 14:2001;1277-1283.
198. Zhou H., Randall L.R., Goldsby R., Smith L., Coffin C.M. HER-2/neu staining in osteosarcoma: association with increased risk of metastasis. Mod Pathol. 14:2001;19A.
199. Thomas D.G., Giordano T.J., Sanders D., Biermann J.S., Baker L. Absence of HER/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res. 8:2002;788-793.
200. Rong S., Jeffers M., Resau J.H., Tsarfaty I., Oskarsson M., Vande Woude G.F. Met expression and sarcoma tumorigenicity. Cancer Res. 53:1993;5355-5360.
201. Ferracini R., Di Renzo M.F., Scotlandi K., Baldini N., Olivero M., Lollini P.L., Cremona O., Campanacci M., Comoglio P.M. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene. 10:1995;739-749.
202. Scotlandi K., Baldini N., Oliviero M., Di Renzo M.F., Martano M., Serra M., Manara M.C., Comoglio P.M., Ferracini R. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol. 149:1996;1209-1219.
203. Naka T., Iwamoto Y., Shinohara N., Ushijima M., Chuman H., Tsuneyoshi M. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol. 10:1997;832-838.
204. Burrow S., Andrulis I.L., Pollak M., Bell R.S. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol. 69:1998;21-27.
205. Benini S., Baldini N., Manara M.C., Chano T., Serra M., Rizzi S., Lollini P.-L., Picci P., Scotlandi K. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer. 80:1999;581-588.
206. 1 to S phase transition. J Biol Chem. 272:1997;4483-4492.
207. Guo W., Healey J.H., Meyers P.A., Ladanyi M., Huvos A.G., Bertino J.R., Gorlick R. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 5:1999;621-627.
208. Zijlstra J.G., de Jong S., de Vries E.G., Mulder N.H. Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother. 7:1990;11-18.
209. Grant C.E., Valdimarsson G., Hipfner D.R., Almquist K.C., Cole S.P.C., Deeley R.G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54:1994;357-361.
210. Baldini N., Scotlandi K., Barbanti-Bròdano G., Manara M.C., Maurici D., Bacci G., Bertoni F., Picci P., Sottili S., Campanacci M., Serra M. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 333:1995;1380-1385.
211. Baldini N., Scotlandi K., Serra M., Picci P., Bacci G., Sottili S., Campanacci M. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res. 17:1999;629-632.
212. Loe D.W., Deeley R.G., Cole S.P. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer. 32A:1996;945-957.
213. Scotlandi K., Serra M., Nicoletti G., Vaccari M., Manara M.C., Nini G., Landuzzi L., Colacci A., Bacci G., Bertoni F., Picci P., Campanacci M., Baldini N. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res. 56:1996;2434-2439.
214. Scotlandi K., Manara M.C., Serra M., Benini S., Maurici D., Caputo A., De Giovanni C., Lollini P.-L., Nanni P., Picci P., Campanacci M., Baldini N. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene. 18:1999;739-746.
215. Chan H.S.L., Grogan T.M., Haddad G., DeBoer G., Ling V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst. 89:1997;1706-1715.
216. Almasan A., Yin Y., Kelly R.E., Lee E.Y.-H.P., Bradley A., Li W., Bertino J.R., Wahl G.M. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes and apoptosis. Proc Natl Acad Sci USA. 92:1995;5436-5440.
217. Banerjee D., Schnieders B., Fu J.Z., Adhikari D., Zhao S.-C., Bertino J.R. Role of E2F-1 in chemosensitivity. Cancer Res. 58:1998;4292-4296.
218. Hochhauser D., Schnieders B., Ercikan-Abali E., Gorlick R., Muise-Helmericks R., Li W.-W., Fan J., Banerjee D., Bertino J.R. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst. 88:1996;1269-1275.
219. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Housman D.E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
220. Banerjee D., Lenz H.-J., Schnieders B., Manno D.J., Ju J.F., Spears C.P., Hochhauser D., Danenberg K., Danenberg P., Bertino J.R. Transfection of wild-type but not mutant P53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Cell Growth Differ. 6:1995;1405-1413.
221. Livingstone L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type P53. Cell. 70:1992;923-935.
222. Yin Y., Tainsky M.A., Bischoff F.Z., Strong L.C., Wahl G.M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 70:1992;937-948.
223. Srimatkandada S., Medina W.D., Cashmore A.R., Whyte W., Engel D., Moroson B.A., Franco C.T., Dube S.K., Bertino J.R. Amplification and organization of dihydrofolate reductase genes in a human leukemia cell line, K-562, resistant to methotrexate. Biochemistry. 22:1983;5774-5781.
224. Schweitzer B.I., Dicker A.P., Bertino J.R. Dihydrofolate reductase as a therapeutic target. FASEB J. 4:1990;2441-2452.
225. Bacci G., Picci P., Orlandi M., Avella M., Manfrini M., Pignatti G., Dallari D., Manduchi R. Prognostic value of serum alkaline phosphatase in osteosarcoma. Tumori. 73:1987;331-336.
226. Bacci G., Ferrari S., Sangiorgi L., Picci P., Casadei R., Orlandi M., Iantorno D., Battistini A., Zanone A. Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. J Chemother. 6:1994;204-210.
227. Yoshikawa H., Takaoka K., Masuhara K., Ono K., Sakamoto Y. Prognostic significance of bone morphogenetic activity in osteosarcoma tissue. Cancer. 61:1988;569-573.
228. Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., Helmke K., Kotz R., Salzer-Kuntschik M., Werner M., Winkelmann W., Zoubek A., Jürgens H., Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 20:2002;776-790.
229. Huvos A.G., Rosen G., Marcove R.C. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en block resection and prosthetic bone replacement. Arch Pathol Lab Med. 101:1977;14-18.
230. Rosen G., Caparros B., Huvos A.G., Kosloff C., Nirenberg A., Cacavio A., Marcove R.C., Lane J.M., Mehta B., Urban C. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 49:1982;1221-1230.
231. Meyers P.A., Gorlick R., Heller G., Casper E., Lane J., Huvos A.G., Healey J.H. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 16:1998;2452-2458.
232. Okada K., Hasegawa T., Yokoyama R. Rosette-forming epithelioid osteosarcoma: a histologic subtype with highly aggressive clinical behavior. Hum Pathol. 32:2001;726-733.
233. Meyers P. Prognostic factors for sarcomas: hard and soft. J Clin Oncol. 20:2002;627-629.
234. Lee P.D., Noble-Topham S.E., Bell R.S., Andrulis I.L. Quantitative analysis of multidrug resistance gene expression in human osteosarcomas. Br J Cancer. 74:1996;1046-1050.
235. Pösl M., Amling M., Grahl K., Hentz M., Ritzel H., Werner M., Winkler K., Delling G. P-glycoprotein expression in high grade central osteosarcoma and normal bone cells: an immunohistochemical study. Gen Diagn Pathol. 142:1997;317-325.
236. Shnyder S.D., Hayes A.J., Pringle J., Archer C.W. P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma. Br J Cancer. 78:1998;757-759.
237. Wunder J.S., Bull S.B., Aneliunas V., Lee P.D., Davis A.M., Beauchamp C.P., Conrd E.U., Grimer R.J., Healey J.H., Rock M.J., Bell R.S., Andrulis I.L. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol. 18:2000;2685-2694.
238. Mesa-Tejada R. p-glycoprotein and multidrug resistance. [Letter] N Engl J Med. 334:1996;1335-1336.
239. Kandel R.A., Campbell S., Noble-Topham S., Bell R., Andrulis I.L. Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas: pilot study. Diagn Mol Pathol. 4:1995;59-65.
240. Stein U., Shoemaker R.H., Schlag P.M. MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Eur J Cancer. 32A:1996;86-92.
241. Beck W.T., Grogan T.M., Willman C.L., Cordon-Cardo C., Parham D.M., Kuttesch J.F., Andreeff M., Bates S.E., Berard C.W., Boyett J.M., Brophy N.A., Broxterman H.J., Chan H.S.L., Dalton W.S., Dietl M., Fojo A.T., Gascoyne R.D., Head D., Houghton P.J., Srivastava D.K., Lehnert M., Leith C.P., Paietta E., Pavelic Z.P., Rimsza L., Roninson I.B., Sikic B.I., Twentyman P.R., Warnke R., Weinstein R. Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 56:1996;3010-3020.
242. Marie J.P., Legrand O., Perrot J.Y., Chevillard S., Huet S., Robert J. Measuring multidrug resistance expression in human malignancies: elaboration of consensus recommendations. Semin Hematol. 34:(4 suppl 5):1997;63-71.
243. Pall G., Spitaler M., Hoffman J., Thaler J., Ludescher C. Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia. 11:1997;1067-1072.
244. Kusuzaki K., Hirata M., Takeshita H., Murata H., Hashiguchi S., Ashihara T., Hirasawa Y. Relationship between P-glycoprotein positivity, doxorubicin binding ability and histologic response to chemotherapy in osteosarcomas. Cancer Lett. 138:1999;203-208.
245. Tsuchiya T., Sekine K., Hinohara S., Namiki T., Nobori T., Kaneko Y. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 120:2000;91-98.
246. Kreicbergs A., Broström L.-Å., Cewrien G., Einhorn S. Cellular DNA content in human osteosarcoma: aspects on diagnosis and prognosis. Cancer. 50:1982;2476-2481.
247. Kreicbergs A., Silfverswärd C., Tribukait B. Flow DNA analysis of primary bone tumors: relationship between cellular DNA content and histopathologic classification. Cancer. 53:1984;129-136.
248. Kusuzaki K., Takeshita H., Murata H., Hirata M., Hashiguchi S., Ashihara T., Hirasawa Y. Prognostic significance of DNA ploidy pattern in osteosarcomas in association with chemotherapy. Cancer Lett. 137:1999;27-33.
249. Guo W., Gorlick R., Ladanyi M., Meyers P.A., Huvos A.G., Bertino J.R., Healey J.H. Expression of bone morphogenetic proteins and their receptors in sarcomas. Clin Orthop. 365:1999;175-183.
250. Yamamura H., Yoshikawa H., Tatsuta M., Akedo H., Takahashi K. Expression of the smooth muscle calponin gene in human osteosarcoma and its possible association with prognosis. Int J Cancer. 79:1998;245-250.
251. Scotlandi K., Serra M., Manara M.C., Maurici D., Benini S., Nini G., Campanacci M., Baldini N. Clinical relevance of Ki-67 expression in bone tumors. Cancer. 75:1995;806-814.
252. Kloen P., Gebhardt M.C., Perez-Atayde A., Rosenberg A.E., Springfield D.S., Gold L.I., Mankin H.J. Expression of transforming growth factor-β (TGF-β) isoforms in osteosarcomas: TGF-β3 is related to disease progression. Cancer. 80:1997;2230-2239.
253. Uozaki H., Horiuchi H., Ishida T., Iijima T., Imamura T., Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase π, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Cancer. 79:1997;2336-2344.
254. Granger M.P., Wright W.E., Shay J.W. Telomerase in cancer and aging. Crit Rev Oncol Hematol. 41:2002;29-40.
255. Yan P., Coindre J.-M., Benhattar J., Bosman F.T., Guillou L. Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: correlation with grade, histology, and proliferative activity. Cancer Res. 59:1999;3166-3170.
256. Aue G., Muralidhar B., Schwartz H.S., Butler M.G. Telomerase activity in skeletal sarcomas. Ann Surg Oncol. 5:1998;627-634.
257. Ulaner G.A., Huang H.-Y., Otero J., Zhao Z., Ben-Porat L., Satagopan J.M., Gorlick R., Meyers P., Healey J.H., Huvos A.G., Hoffman A.R., Ladanyi M. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 63:2003;1759-1763.
258. Sangiorgi L., Gobbi G.A., Lucarelli E., Menghi Sartorio S., Mordenti M., Ghedini I., Maini V., Scrimieri F., Reggiani M., Zambon Bertoja A., Benassi M.S., Picci P. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int J Cancer. 95:2001;156-161.
259. Kido A., Schneider-Stock R., Hauptmann K., Roessner A. Telomerase activity in benign bone tumors and tumor-like lesions. Pathol Res Pract. 195:1999;753-757.
260. Biegel J.A., Womer R.B., Emanuel B.S. Complex karyotypes in a series of pediatric osteosarcomas. Cancer Genet Cytogenet. 38:1989;89-100.
261. Mertens F., Mandahl N., Örndal C., Baldetorp B., Bauer H.C.F., Rydholm A., Wiebe T., Willén H., Åkerman M., Heim S., Mitelman F. Cytogenetic findings in 33 osteosarcomas. Int J Cancer. 55:1993;44-50.
262. Bridge J.A., Nelson M., McComb E., McGuire M.H., Rosenthal H., Vergara G., Maale G.E., Spanier S., Neff J.R. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet. 95:1997;74-87.
263. Scheffer H., Kruize Y.C.M., Osinga J., Kjuen G., Oosterhuis J.W., Leeuw J.A., Schraffordt Koops H., Buys C.H.C.M. Complete association of loss of heterozygosity of chromosomes 13 and 17 in osteosarcoma. Cancer Genet Cytogenet. 53:1991;45-55.
264. Human gene mapping 11. London Conference (1991). Eleventh International Workshop on Human Gene Mapping. London, UK, August 18-22, 1991. Cytogenet Cell Genet. 58:1991;1161-1163.
265. Craig I., Gemmill R., Kucherlapati R. Report of the first international workshop on human chromosome 12 mapping. Cytogenet Cell Genet. 61:1992;243-251.
266. Fox J.L., Hsu P.-H., Legator M.S., Morrison L.E., Seelig S.A. Fluorescence in situ hybridization: powerful molecular tool for cancer prognosis. Clin Chem. 41:1995;1554-1559.
267. Ozisik Y.Y., Meloni A.M., Peier A., Altungoz O., Spanier S.S., Zalupski M.M., Leong S.P.L., Sandberg A.A. Cytogenetic findings in 19 malignant bone tumors. Cancer. 74:1994;2268-2275.
268. Pearson A.D.J., Reid M.M., Davison E.V., Bown N., Malcolm A.J., Craft A.W. Cytogenetic investigations of solid tumours of children. Arch Dis Child. 63:1988;1012-1015.
269. Grubb G., Hoctor V., Venter D., Choong P. Inversion (6)(p23q15) as the sole anomaly in a low-grade intraosseous osteosarcoma. Cancer Genet Cytogenet. 109:1999;70-71.
270. Dodd L.G., Scully S., Harrelson J.M. Utility of fine needle aspiration in the diagnosis of primary osteosarcoma. Mod Pathol. 14:2001;11A.
271. Åkerman M., Dreinhöfer K., Rydholm A., Willén H., Mertens F., Mitelman F., Mandahl N. Cytogenetic studies on fine-needle aspiration samples from osteosarcoma and Ewing's sarcoma. Diagn Cytopathol. 15:1996;17-22.
272. Tarkkanen M., Nordling S., Böhling T., Kivioja A., Karaharju E., Szymanska J., Elomaa I., Knuutila S. Comparison of cytogenetic, interphase cytogenetics, and DNA flow cytometry in bone tumors. Cytometry. 26:1996;185-191.
273. Al-Romaih K., Bayani J., Vorobyova L., Karaskova J., Park P.C., Zielenska M., Squire J.A. Chromosomal instability (CIN) in osteosarcoma and its association with centrosome abnormalities. Cancer Genet Cytogenet. 2003;. (in press).
274. Kallioniemi O.-P., Kallioniemi A., Piper J., Isola J., Waldman F.M., Gray J.W., Pinkel D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 10:1994;231-243.
275. Piper J. Computer image analysis of comparative genomic hybridization. Cytometry. 19:1995;10-26.
276. Bentz M., Plesch A., Stilgenbauer S., Döhner H., Lichter P. Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer. 21:1998;172-175.
277. Bryndorf T., Kirchhoff M., Rose A., Maahr J., Gerdes T., Karhu R., Kallioniemi A., Christensen B., Lundsteen C., Philip J. Comparative genomic hybridization in clinical cytogenetics. Am J Hum Genet. 57:1995;1211-1220.
278. Stock C., Kager L., Fink F.-M., Gadner H., Ambros P.F. Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer. 28:2000;329-336.
279. Menghi-Sartorio S., Mandahl N., Mertens F., Picci P., Knuutila S. DNA copy number amplifications in sarcomas with homogeneously staining regions and double minutes. Cytometry. 46:2001;79-84.
280. Zielenska M., Bayani J., Pandita A., Toledo S., Marrano P., Andrade J., Petrilli A., Thorner P., Sorensen P., Squire J.A. Comparative genomic hybridization analysis identifies gains of 1p35∼p36 and chromosome 19 in osteosarcoma. Cancer Genet Cytogenet. 130:2001;14-21.
281. Tarkkanen M., Karhu R., Kallioniemi A., Elomaa I., Kivioja A.H., Nevalainen J., Böhling T., Karaharju E., Hyytinen E., Knuutila S., Kallioniemi O.-P. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res. 55:1995;1334-1338.
282. Tarkkanen M., Aaltonen L.A., Böhling T., Kivioja A., Karaharju E., Elomaa I., Knuutila S. No evidence of microsatellite instability in bone tumours. Br J Cancer. 74:1996;453-455.
283. van Kessel A.G., dos Santos N.R., Simons A., de Bruijn D., Forus A., Fodstad Ø., Myklebost O., Balemans M., Baats E., Weghuis D.O., Suijkerbuijk R.F., van den Berg E., Molenaar M., de Leeuw B. Molecular cytogenetics of bone and soft tissue tumors. Cancer Genet Cytogenet. 95:1997;67-73.
284. Brinkschmidt C., Blasius S., Bürger H., Simon R., Diallo R., Battmann A., Winkelmann W., Böcker W., Dockhorn-Dworniczak B. Novel amplicons in high-grade osteosarcomas detected by comparative genomic hybridization (CGH). Verh Dtsch Ges Pathol. 82:1998;184-188.
285. Tarkkanen M., Böhling T., Gamberi G., Ragazzini P., Benassi M.S., Kivioja A., Kallio P., Elomaa I., Picci P., Knuutila S. Comparative genomic hybridization of low-grade central osteosarcoma. Mod Pathol. 11:1998;421-426.
286. Ozaki T., Schaefer K.-L., Wai D., Buerger H., Flege S., Lindner N., Kevric M., Diallo R., Bankfalvi A., Brinkschmidt C., Juergens H., Winkelmann W., Dockhorn-Dworniczak B., Bielack S.S., Poremba C. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer. 102:2002;355-365.
287. Forus A., Weghuis D.O., Smeets D., Fodstad Ø., Myklebost O., van Kessel A.G. Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas . Genes Chromosomes Cancer. 14:1995;8-14.
288. Wolf M., Tarkkanen M., Hulsebos T., Larramendy M.L., Forus A., Myklebost O., Aaltonen L.A., Elomaa I., Knuutila S. Characterization of the 17p amplicon in human sarcomas: microsatellite marker analysis. Int J Cancer. 82:1999;329-333.
289. van Dartel M., Cornelissen P.W.A., Redeker S., Tarkkanen M., Knuutila S., Hogendoorn P.C.W., Westerveld A., Gomes I., Bras J., Hulsebos T.J.M. Amplification of 17p11.2-p12, including PMP22, TOP3A, and MAPK7 in high-grade osteosarcoma. Cancer Genet Cytogenet. 139:2002;91-96.
290. Bayani J., Zielenska M., Pandita A., Al-Romaih K., Karaskova J., Harrison K., Brige J.A., Sorensen P., Thorner P., Squire J.A. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer. 36:2003;7-16.
291. Gisselsson D., Höglund M., Mertens F., Mitelman F., Mandahl N. Chromosomal organization of amplified chromosome 12 sequences in mesenchymal tumors detected by fluorescence in situ hybridization. Genes Chromosomes Cancer. 23:1998;203-212.
292. Gisselsson D., Pälsson E., Höglund M., Domanski H., Mertens F., Pandis N., Sciot R., Dal Cin P., Bridge J.A., Mandahl N. Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer. 33:2002;133-140.
293. Murata H., Kusuzaki K., Takeshita H., Hirasawa Y., Ashihara T., Abe T., Inazawa J. Aberrations of chromosomes 1 and 17 in six human osteosarcoma cell lines using double-target fluorescence in situ hybridization. Cancer Genet Cytogenet. 107:1998;7-10.
294. Murata H., Kusuzaki K., Hirasawa Y., Ashihara T., Abe T., Inazawa J. Relationship between chromosomal aberrations by fluorescence in situ hybridization and DNA ploidy by cytofluorometry in osteosarcoma. Cancer Lett. 139:1999;221-226.
295. Wang H., Rodger W.H., Chmell M.J., Svitek C., Schwartz H.S. Osteosarcoma oncogene expression detected by in situ hybridization. J Orthop Res. 13:1995;671-678.
296. Wolf M., El-Rifai W., Tarkkanen M., Kononen J., Serra M., Eriksen E.F., Elomaa I., Kallioniemi A., Kallioniemi O.-P., Knuutila S. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet. 123:2000;128-132.
297. Forus A., Meza-Zepeda L.A., Khan J., Dahlberg A.B., Godager L., South A., Nizetic D., Marenholz I., Lioumi M., Ragoussis I., Maelandsmo G.M., Flørenes V.A., Henriksen J., Nesland J., Serra M., Mischke D., Tarkkanen M., Knuutila S., Meltzer P.S., Myklebost O. Molecular profiling of sarcomas: microarray analysis of osteosarcomas and isolation of three novel candidate genes from 1q21 amplicon. [Abstract] Cancer Genet Cytogenet. 128:2001;59.
298. Siegel H., Bolander M., Dion N., Sarkar G., Rock M., Hatano H. Expression profiling of osteogenic sarcoma: a potential diagnostic and prognostic tool. Trans Orthop Res Soc. 2002;. Poster 0756.
299. Schofield D., Triche T.J., Wai D. Expression profiling of bone tumors. Ladanyi M., Gerald W.L. Expression profiling of human tumors: diagnostic and research applications. 2003;Humana Press, Totowa, NJ.
300. Sinovic J.F., Bridge J.A., Neff J.R. Ring chromosome in parosteal osteosarcoma: clinical and diagnostic significance. Cancer Genet Cytogenet. 62:1992;50-52.
301. Szymanska J., Mandahl N., Mertens F., Tarkkanen M., Karaharju E., Knuutila S. Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: a combined cytogenetic and comparative genomic hybridization study. Genes Chromosomes Cancer. 16:1996;31-34.
302. Unni K.K., Dahlin D.C., Beabout J.W., Ivins J.C. Parosteal osteosarcoma. Cancer. 37:1976;2466-2475.
303. Sheth D.S., Yasko A.W., Raymond A.K., Ayala A.G., Carrasco C.H., Benjamin R.S., Jaffe N., Murray J.A. Conventional and dedifferentiated parosteal osteosarcoma: diagnosis, treatment, and outcome. Cancer. 78:1996;2136-2145.
304. Sciot R., Samson I., Dal Cin P., Lateur L., Van Damme B., Van den Berghe H., Desmet V. Giant cell rich parosteal osteosarcoma. Histopathology. 27:1995;51-55.
305. Noble-Topham S.E., Burrow S.R., Eppert K., Kandel R.A., Meltzer P.S., Bell R.S., Andrulis I.L. SAS is amplified predominantly in surface osteosarcoma. J Orthop Res. 14:1996;700-705.
306. Wunder J.S., Eppert K., Burrow S.R., Gogkoz N., Bell R.S., Andrulis K.L. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene. 18:1999;783-788.
307. Gamberi G., Ragazzini P., Benassi M.S., Ferrari C., Sollazzo M.R., Molendini L., Merli M., Magagnoli G., Ruggieri P., Balladelli A., Orlando C., Bacchini P., Pazzagli M., Picci P. Analysis of 12q13-15 genes in parosteal osteosarcoma. Clin Orthop. 377:2000;195-204.
308. Ahmad S.A., Patel S.R., Ballo M.T., Baker T.P., Yasko A.W., Wang X., Feig B.W., Hunt K.K., Lin P.P., Weber K.L., Chen L.L., Zagars G.K., Pollock R.E., Benjamin R.S., Pisters P.W.T. Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol. 20:2002;521-527.
309. Jensen M.L., Schumacher B., Jensen O.M., Nielsen O.S., Keller J. Extraskeletal osteosarcomas: a clinicopathologic study of 25 cases. Am J Surg Pathol. 22:1998;588-594.
310. Mohamed A.N., Zalupski M.M., Ryan J.R., Koppitch F., Balcerzak S., Kempf R., Wolman S.R. Cytogenetic aberrations and DNA ploidy in soft tissue sarcoma: a Southwest Oncology Group Study. Cancer Genet Cytogenet. 99:1997;45-53.
311. Mertens F., Fletcher C.D.M., Dal Cin P., De Wever I., Mandahl N., Mitelman F., Rosai J., Rydholm A., Sciot R., Tallini G., Van den Berghe H., Vanni R., Willén H. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP study group. Genes Chromosomes Cancer. 22:1998;16-25.
312. Haslam S.I., Van Hul W., Morales-Piga A., Balemans W., San-Millan J.L., Nakatsuka K., Willems P., Haites N.E., Ralston S.H. Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res. 13:1998;911-917.
313. Klein R.M., Norman A. Diagnostic procedures for Paget disease. Endocrinol Metab Clin North Am. 24:1995;437-450.
314. McNairn J.D.K., Damron T.A., Landas S.K., Ambrose J.L., Shrimpton A.E. Inheritance of osteosarcoma and Paget's disease of bone: a familial loss of heterozygosity study. J Mol Diagn. 3:2001;171-177.
315. Shrimpton A.E., McNairn J.D.K., Landas S.K., Ambrose J.L., Damron T.A. Inheritance of Paget's osteosarcoma: TNFRSF11A (rank) T311T; 933G > A: a not so silent mutation? [Abstract] J Med Diagn. 3:2001;211.
316. Hughes A.E., Ralston S.H., Marken J., Bell C., MacPherson H., Wallace R.G.H., van Hul W., Whyte M.P., Nakatsuka K., Hovy L., Anderson D.M. Mutations of TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 24:2000;45-48.
317. Wuyts W., Van Wesenbeeck L., Morales-Piga A., Ralston S., Hocking L., Vanhoenacker F., Westhovens R., Verbruggen L., Anderson D., Hughes A., Van Hul W. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone. 28:2001;104-107.
318. Beedles K.E., Sharpe P.T., Wagner E.F., Grigoriadis A.E. A putative role for c-Fos in the pathophysiology of Paget's disease. J Bone Miner Res. 14:(suppl 2):1994;21-28.
319. Damron T., McNairn J., Shrimpton A. Inheritance of Paget's osteosarcoma of bone: a loss of heterozygosity study. Trans Orthop Res Soc. 2002;. Poster 0754.
320. Sparks A.B., Peterson S.N., Bell C., Loftus B.J., Hocking L., Cahill D.P., Frassica F.J., Streeten E.A., Levine M.A., Fraser C.M., Adams M.D., Broder S., Venter J.C., Kinzler K.W., Vogelstein B., Ralston S.H. Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. Calcif Tissue Int. 68:2001;151-155.
321. Hansen M.F., Cavenee W.K. Genetics of cancer predisposition. Cancer Res. 47:1987;5518-5527.
322. Serra M., Tarkkanen M., Baldini N., Scotlandi K., Sarti M., Maurici D., Manara M.C., Benini S., Bacchini P., Knuutila S., Picci P. Simultaneous paired analysis of numerical chromosomal aberrations and DNA content in osteosarcoma. Mod Pathol. 14:2001;710-716.
323. Kreicbergs A. DNA cytometry of musculoskeletal tumors: a review. Acta Orthop Scand. 61:1990;282-297.
324. El-Naggar A.K., Hurr K., Tu N., Teague K., Raymond K.A., Ayala A.G., Murray J. DNA and RNA content analysis by flow cytometry in the pathobiologic assessment of bone tumors. Cytometry. 19:1995;256-262.
325. Neuburger M., Xia Y., Herget G.W., Huang Y., Adler C.-P. Prognostic significance of DNA image cytophotometry for osteosarcoma. Anal Quant Cytol Histol. 21:1999;461-467.
326. Ozaki T., Flege S., Liljenqvist U., Hillmann A., Delling G., Salzer-Kuntschik M., Jürgens H., Kotz R., Winkelmann W., Bielack S.S. Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer. 94:2002;1069-1077.
327. Ragland B.D., Bell W.C., Lopez R.R., Siegal G.P. Cytogenetics and molecular biology of osteosarcoma. Lab Invest. 82:2002;365-373.
328. Bauer H.C.F., Kreicbergs A., Silfverswärd C., Tribukait B. DNA
329. Bauer H.C., Kreicbergs A., Silfverswärd C. Prognostication including DNA analysis in osteosarcoma. Acta Orthop Scand. 60:1989;353-360.
330. Hiddemann W., Roessner A., Wörmann B., Mellin W., Klockenkemper B., Bösing T., Büchner T., Grundmann E. Tumor heterogeneity in osteosarcoma as identified by flow cytometry. Cancer. 59:1987;324-328.
331. Mankin H.J., Gebhardt M.C., Springfield D.S., Litwak G.J., Kusuzaki K., Rosenberg A.E. Flow cytometric studies of human osteosarcoma. Clin Orthop. 270:1991;169-180.
332. Schofield D., Triche T.J. cDNA microarray analysis of global gene expression in sarcomas. Curr Opin Oncol. 14:2002;406-411.
333. Seto M., Tomoda R., Morita K., Matsumine A., Shinto Y., Uchida A. In vivo inhibition of osteosarcoma pulmonary metastasis with bystander effect using gene therapy. Trans Orthop Res Soc. 2002;. Poster 0494.
334. McGary E.C., Weber K., Mills L., Doucet M., Lewis V., Lev D.C., Fidler I.J., Bar-Eli M. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res. 8:2002;3584-3591.
335. Haydon R., Zhou L., Jiang W., Breyer B., Feng T., Cheng H., Peabody T., Simon M., He T. Nuclear receptor agonists as effective differentiation therapy agents for human osteosarcoma. Trans Orthop Res Soc. 2002;. Poster 0760.
336. Huvos A.G. Bone tumors: diagnosis, treatment, and prognosis. 1991;WB Saunders, Philadelphia.
337. Dal Cin P., Sciot R., Samson I., De Wever I., Van den Berghe H. Osteoid osteoma and osteoblastoma with clonal chromosome changes. Br J Cancer. 78:1998;344-348.
338. Baruffi M.R., Volpon J.B., Neto J.B., Casartelli C. Osteoid osteomas with chromosome alterations involving 22q. Cancer Genet Cytogenet. 124:2001;127-131.
339. Rosado K.E., Pitt M.J., Siegal G.P. Osteoblastoma: a mimic of osteosarcoma. Pediatr Pathol Mol Med. 19:2000;305-322.
340. Jaffe H.L., Mayer L. An osteoblastic osteoid tissue-forming tumor of metacarpal bone. Arch Surg. 24:1932;500-564.
341. Jaffe H.L. Benign osteoblastoma. Bull Hosp Jt Dis Orthop Inst. 17:1956;141-151.
342. Lichtenstein L. Benign osteoblastoma: a category of osteoid and bone forming tumors other than the classical osteoid osteoma, which may be mistaken for giant cell tumor or osteogenic sarcoma. Cancer. 9:1956;1044-1052.
343. Unni K.K. Dahlin's bone tumors: general aspects and data on 11087 cases. 1996;Lippincott-Raven, Philadelphia.
344. Fechner R.E., Mills S.E. Tumors of bones and joints: atlas of tumor pathology. 3rd series, fascicle 8. 1993;Armed Forces Institute of Pathology, Washington DC.
345. Della Rocca C., Huvos A.G. Osteoblastoma: varied histological presentations with a benign clinical course, an analysis of 55 cases. Am J Surg Pathol. 20:1996;841-850.
346. Angervall L., Persson S., Stenman G., Kindblom L.-G. Large cell, epithelioid, telangiectatic osteoblastoma: a unique pseudosarcomatous variant of osteoblastoma. Hum Pathol. 30:1999;1254-1259.
347. Franchi A., Arganini L., Baroni G., Calzolari A., Capanna R., Campanacci D., Caldora P., Masi L., Brandi M.L., Zampi G. Expression of transforming growth factor β isoforms in osteosarcoma variants: association of TGFβ with high-grade osteosarcomas. J Pathol. 185:1998;284-289.
348. Radig K., Schneider-Stock R., Mittler U., Neumann H.W., Roessner A. Genetic instability in osteoblastic tumors of the skeletal system. Pathol Res Pract. 194:1998;669-677.
349. Mascarello J.T., Krous H.F., Carpenter P.M. Unbalanced translocation resulting in the loss of the chromosome 17 short arm in an osteoblastoma. Cancer Genet Cytogenet. 69:1993;65-67.
350. van den Berg E., Hovinga B., Mastik M.F., Molenaar W.M. Clonal chromosomal aberrations in a case of osteoblastoma. [Abstract] Cancer Genet Cytogenet. 128:2001;83.
351. Martin S.S., Hurt W.G., Hedges L.K., Butler M.G., Schwartz H.S. Microsatellite instability in sarcomas. Ann Surg Oncol. 5:1998;356-360.
352. Wolf M., El-Rifai W., Tarkkanen M., Kononen J., Serra M., Eriksen E.F., Scotlandi K., Elomaa I., Kallioniemi A., Kallioniemi O.-P., Knuutila S. Aberrant gene expression in human osteosarcoma. [Abstract] Cancer Genet Cytogenet. 128:2001;82.
353. Zhang Y.-W., Morita I., Ikeda M., Ma K.-W., Murota S. Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27. Oncogene. 20:2001;4138-4149.
354. Sulzbacher I., Birner P., Trieb K., Träxler M., Lang S., Chott A. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol. 16:2003;66-71.
355. INK4D cyclin dependent kinase inhibitor gene is altered in osteosarcoma. Oncogene. 15:1997;231-235.
356. Henno S., Guinebretiere J.M., Turlin B., Langlais F., Duvillard P., Lancien G. Expression of transforming growth factor beta-1 and beta 3 (TGF-β1 and TGB-β3) in osteosarcomas is correlated with response to chemotherapy. Mod Pathol. 13:2000;10A.
357. Manara M.C., Perbal B., Benini S., Strammiello R., Cerisano V., Perdichizzi S., Serra M., Astolfi A., Bertoni F., Alami J., Yeger H., Picci P., Scotlandi K. The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol. 160:2002;849-859.
358. Naka N., Araki N., Nakanishi H., Itoh K., Mano M., Ishiguro S., de Bruijn D.R.H., Myoui A., Ueda T., Yoshikawa H. Expression of SSX genes in human osteosarcomas. Int J Cancer. 98:2002;640-642.
359. Meza-Zepeda L.A., Forus A., Lygren B., Dahlberg A.B., Godager L.H., South A.P., Marenholz I., Lioumi M., Flørenes V.A., Maelandsmo G.M., Serra M., Mischke D., Nizetic D., Ragoussis J., Tarkkanen M., Nesland J.M., Knuutila S., Myklebost O. Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene. 21:2002;2261-2269.
360. Oda Y., Naka T., Takeshita M., Iwamoto Y., Tsuneyoshi M. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol. 31:2000;709-716.
361. Cui L.-X., Oka T., Dobashi Y., Ishida T., Machinami R. Mutational activation of K-ras gene is absent in human osteosarcoma. Med Sci Res. 19:1991;697-698.
362. Antillón-Klüssmann F., García-Delgado M., Villa-Elízaga I., Sierrasesúmaga L. Mutational activation of ras genes is absent in pediatric osteosarcoma. Cancer Genet Cytogenet. 79:1995;49-53.
363. Reith J., Casanova J., Scarborough M. CD44 and CD44V6 expression in osteosarcoma. Mod Pathol. 14:2001;18A.
364. Weber G.F., Bronson R.T., Hagan J., Cantor H., Schmits R., Mak T.W. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res. 62:2002;2281-2286.
365. Bagué S., Esteller M., Lemma E., Baylin S.B., Herman J.G., Majó J., Cáceres E., Prat J. GSTP1 hypermethylation after chemotherapy in osteosarcomas. Mod Pathol. 14:2001;9A.
366. Hicks J., Shohet J., Nuchertern J., Lau C., Johnson M., Rudman D., Ge Y., Chintagumpala M. Minichromosome maintenance protein 7 (MCM7) expression in osteosarcoma: an immunocytochemical study. Mod Pathol. 15:2002;311A.
367. Rosenberg A.E., Harris K.R., Keel S.B., Roth S.I., Nielsen G.P., Mangham C. Immunohistochemical analysis of primary osteosarcoma of bone. Mod Pathol. 15:2002;22A.
368. Liehr T., Park O., Feuerstein B.G., Gebhart E., Rautenstrauss B. The peripheral myelin protein 22 kDa (PMP22) gene is amplified in cell lines derived from glioma and osteogenic sarcoma: a new candidate for an oncogene? Int J Oncol. 10:1997;915-919.
369. Haydon R.C., Zhou L., Feng T., Breyer B., Cheng H., Jiang W., Ishikawa A., Peabody T., Montag A., Simon M.A., He T.-C. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res. 8:2002;1288-1294.
370. Kawaguchi S., Uede T. Distribution of integrins and their matrix ligands in osteogenic sarcomas. J Orthop Res. 11:1993;386-395.
371. Kashima T., Kawaguchi J., Takeshita S., Kuroda M., Takanashi M., Horiuchi H., Imamura T., Ishikawa Y., Ishida T., Mori S., Machinami R., Kudo A. Anomalous cadherin expression in osteosarcoma: possible relationship to metastasis and morphogenesis. Am J Pathol. 155:1999;1549-1555.
372. Sato H., Hasegawa T., Abe Y., Sakai H., Hirohashi S. Expression of E-cadherin in bone and soft tissue sarcomas: a possible role in epithelial differentiation. Hum Pathol. 30:1999;1344-1349.
373. Sulzbacher I., Träxler M., Mosberger I., Lang S., Chott A. Platelet-derived growth factor-AA and -α receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol. 13:2000;632-637.
374. Häckel C., Ueda Y., Tsuchya H., Herrera A., Blasius S., Roessner A. Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors. Zentralbl Pathol. 140:1994;363-369.
375. Reith J., Casanova J., Scarborough M. Fas (CD95) and Fas-ligand (CD95-L) expression in osteosarcoma (OS): analysis of 93 cases. Mod Pathol. 14:2001;18A.
376. Smithey B.E., Pappo A.S., Hill D.A. c-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol. 26:2002;486-492.
377. Haydon R.C., Deyrup A., Ishikawa A., Heck R., Jiang W., Zhou L., Feng T., King D., Cheng H., Breyer B., Peabody T., Simon M.A., Montag A.G., He T.-C. Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma. Int J Cancer. 102:2002;338-342.
378. Forus A., Flørenes V.A., Maelandsmo G.M., Fodstad Ø., Myklebost O. The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas. Cancer Genet Cytogenet. 78:1994;165-171.
379. Navarro S., Pellín A., Noguera R., Díaz M.P., Tsokos M., Triche T.J., Llombart-Bosch A. dbl oncogene expression in childhood tumors and tumor cell lines. Diagn Mol Pathol. 2:1993;158-162.
380. Mitchell D.S., Guan X.-Y., Meltzer P.S. Detection of chromosome 12q amplification in sarcomas by chromosome microdissection and interphase FISH. Int J Oncol. 5:1994;787-792.
381. Sawyer J., Lukacs J., Gilliland J., Tryka F., Savell V., Parham D., Thomas J., Nicholas R. Multicolor spectral karyotyping of bone and cartilage tumors. [Abstract] Cancer Genet Cytogenet. 123:2000;90.
382. Ozaki T., Neumann T., Wai D., Schäfer K.-L., van Valen F., Lindner N., Scheel C., Böcker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C. Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping. Cancer Genet Cytogenet. 140:2003;145-152.
383. Lefèvre S.-H., Vogt N., Dutrillaux A.-M., Chauveinc L., Stoppa-Lyonnet D., Doz F., Desjardins L., Dutrillaux B., Chevillard S., Malfoy B. Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma. Oncogene. 20:2001;8092-8099.
384. Lucio E., Ololade O., Adegboyega P.A. Expression of prostaglandin H-synthase (COX2) in osteoid osteoma. Mod Pathol. 14:2001;15A.
385. Panizo C., Patiño A., Calasanz M.J., Rifón J., Sierrasesúmaga L., Rocha E. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutations. Med Pediatr Oncol. 30:1998;165-169.
386. Aung L., Gorlick R.G., Shi W., Thaler H., Shorter N.A., Healey J.H., Huvos A.G., Meyers P.A. Second malignant neoplasms in long-term survivors in osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience. Cancer. 95:2002;1728-1734.
387. Kim B., Lee-Yoon D. Correlations between galectin-3 expression and tumor invasiveness in human osteosarcoma cell lines. Trans Orthop Res Soc. 2001;. Poster 0858.
388. Ito Y., Pandey P., Sporn M., Kharbanda S., Kufe D. Involvement of caspase-8 in the induction of osteosarcoma cell apoptosis by the novel triterpenoid CDDO. Trans Orthop Res Soc. 2001;. Poster 0863.
389. García-Castellano J.M., Villanueva A., Healey J.H., Sowers R., Cordon-Cardo C., Huvos A., Bertino J.R., Meyers P., Gorlick R. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res. 8:2002;783-787.
390. Nagamori M., Kawaguchi S., Hayakawa M., Wada T., Nagoya S., Yamashita T., Ishii S., Murakami M., Inobe M., Uede T. Induction of anti-tumor immunity on osteosarcoma by exogenous expression of B7-1A, an alternatively spliced form of B7-1 costimulatory adhesion molecule. Trans Orthop Res Soc. 2001;. Poster 0840.
391. Sarkar G., Dion N., Bolander M. Preferential amplification of coding sequences (PACS): a novel approach to identifying genetic markers for osteogenic sarcoma and other skeletal tumors. Trans Orthop Res Soc. 2002;. Poster 0757.
392. Varelias A., Koblar S.A., Cowled P.A., Carter C.D., Clayer M. Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis. Cancer. 95:2002;862-869.
393. Wunder J.S., Bell R.S., Wold L., Andrulis I.L. Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Orthop Res. 11:1993;396-403.
394. Rosier R.N., Teot L.A., Hicks D.G., Schwartz C., O'Keefe R.J., Puzas J.E. Multiple drug resistance in osteosarcoma. Iowa Orthop J. 15:1995;66-73.
395. Boulares A.H., Zoltoski A.J., Sherif Z.A., Yakovlev A.G., Smulson M.E. The poly(ADP-ribose) polymerase-1-regulated endonuclease DNAS1L3 is required for etoposide-induced internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells. Cancer Res. 62:2002;4439-4444.
396. Yang R., Sowers R., Mazza B.A., Healey J.H., Huvos A., Grier H., Bernstein M., Beardsley G.P., Krailo M.D., Devidas M., Bertino J.R., Meyers P.A., Gorlick R. Sequence alterations in the reduced folate carrier are observed in osteosarcoma samples. Clin Cancer Res. 9:2003;837-844.
397. Dressler L.G., Duncan M.H., Varsa E.E., McConnell T.S. DNA content measurement can be obtained using archival material for DNA flow cytometry: a comparison with cytogenetic analysis in 56 pediatric solid tumors. Cancer. 72:1993;2033-2041.
398. López-Ginés C., Carda-Batalla C., López-Terrada L., Llombart-Bosch A. Presence of double minutes and monosomy 17p in xenografted human osteosarcomas. Cancer Genet Cytogenet. 90:1996;57-62.
399. Gunawardena S., Chintagumpala M., Trautwein L., Brewer E., Gresik M.V., Hicks M.J., Harrison W.R., Morad A., Cooley L.D. Multifocal osteosarcoma: an unusual presentation. J Pediatr Hematol Oncol. 21:1999;58-62.
400. Mertens F., Larramendy M., Gustavsson A., Gisselsson D., Rydholm A., Brosjö O., Mitelman F., Knuutila S., Mandahl N. Radiation-associated sarcomas are characterized by complex karyotypes with frequent rearrangements of chromosome arm 3p. Cancer Genet Cytogenet. 116:2000;89-96.
401. Batanian J.R., Cavalli L.R., Aldosari N.M., Ma E., Sotelo-Avila C., Ramos M.B., Rone J.D., Thorpe C.M., Haddad B.R. Evaluation of paediatric osteosarcomas by classic cytogenetic and CGH analyses. Mol Pathol. 55:2002;389-393.
402. Tarkkanen M., Wiklund T.A., Virolainen M.J., Larramendy M.L., Mandahl N., Mertens F., Blomqvist C.P., Tukiainen E.J., Miettinen M.M.A., Elomaa A.I., Knuutila Y.S. Comparative genomic hybridization of postirradiation sarcomas. Cancer. 92:2001;1992-1998.
403. Örndal C., Mandahl N., Rydholm A., Willén H., Brosjö O., Heim S., Mitelman F. Supernumerary ring chromosomes in five bone and soft tissue tumors of low or borderline malignancy. Cancer Genet Cytogenet. 60:1992;170-175.
404. Johnson-Pais T.L., Nellis M.J., Ammerman D.G., Pathmanathan D., Bhatia P., Buller C.L., Leach R.J., Hansen M.F. Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. Int J Cancer. 105:2003;285-288.